Regular Aspirin Use Increases Risk Of Crohn’s Disease
People who take aspirin regularly for a year or more may be at an increased risk of developing Crohn’s disease, according to a new study by the University of East Anglia (UEA).
Led by Dr Andrew Hart of UEA’s School of Medicine, the research was presented for the first time at the Digestive Disease Week conference in New Orleans on May 3.
Crohn’s disease is a serious condition affecting 60,000 people in the UK and 500,000 people in the US. It is characterized by inflammation and swelling of any part of the digestive system. This can lead to debilitating symptoms and requires patients to take life-long medication. Some patients need surgery and some sufferers have an increased risk of bowel cancer.
Though there are likely to be many causes of the disease, previous work on tissue samples has shown that aspirin can have a harmful effect on the bowel. To investigate this potential link further, the UEA team followed 200,000 volunteers aged 30-74 in the UK, Sweden, Denmark, Germany and Italy. The volunteers had been recruited for the EPIC study (European Prospective Investigation into Cancer and Nutrition) between 1993 and 1997.
The volunteers were all initially well, but by 2004 a small number had developed Crohn’s disease. When looking for differences in aspirin use between those who did and did not develop the disease, the researchers discovered that those taking aspirin regularly for a year or more were around five times more likely to develop Crohn’s disease.
The study also showed that aspirin use had no effect on the risk of developing ulcerative colitis ““ a condition similar to Crohn’s disease.
“This is early work but our findings do suggest that the regular use of aspirin could be one of many factors which influences the development of this distressing disease in some patients,” said Dr Hart.
“Aspirin does have many beneficial effects, however, including helping to prevent heart attacks and strokes. I would urge aspirin users to continue taking this medication since the risk of aspirin users possibly developing Crohn’s disease remains very low ““ only one in every 2000 users, and the link is not yet finally proved.”
Further work must now be done in other populations to establish whether there is a definite link and to check that aspirin use is not just a marker of another risk factor which is the real cause of Crohn’s disease. The UEA team will also continue its wider research into other potential factors in the development of Crohn’s disease, including diet.
On the Net: